Aeglea Bio Therapeutics Probability of Future Stock Price Finishing Over 0.13
| AGLEDelisted Stock | USD 0.59 0.01 1.72% |
Aeglea |
Aeglea Bio Target Price Odds to finish over 0.13
The tendency of Aeglea Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to stay above $ 0.13 in 90 days |
| 0.59 | 90 days | 0.13 | about 77.78 |
Based on a normal probability distribution, the odds of Aeglea Bio to stay above $ 0.13 in 90 days from now is about 77.78 (This Aeglea Bio Therapeutics probability density function shows the probability of Aeglea Stock to fall within a particular range of prices over 90 days) . Probability of Aeglea Bio Therapeutics price to stay between $ 0.13 and its current price of $0.59 at the end of the 90-day period is about 75.16 .
Given the investment horizon of 90 days the stock has the beta coefficient of 4.92 . This suggests as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Aeglea Bio will likely underperform. In addition to that Aeglea Bio Therapeutics has an alpha of 4.237, implying that it can generate a 4.24 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Aeglea Bio Price Density |
| Price |
Predictive Modules for Aeglea Bio
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Aeglea Bio Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Aeglea Bio Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Aeglea Bio is not an exception. The market had few large corrections towards the Aeglea Bio's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Aeglea Bio Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Aeglea Bio within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 4.24 | |
β | Beta against Dow Jones | 4.92 | |
σ | Overall volatility | 0.17 | |
Ir | Information ratio | 0.12 |
Aeglea Bio Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Aeglea Bio for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Aeglea Bio Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Aeglea Bio is not yet fully synchronised with the market data | |
| Aeglea Bio has some characteristics of a very speculative penny stock | |
| Aeglea Bio has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 2.33 M. Net Loss for the year was (83.81 M) with loss before overhead, payroll, taxes, and interest of (262 K). | |
| Aeglea Bio Therapeutics currently holds about 73.68 M in cash with (80.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.2, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 98.0% of the company shares are held by institutions such as insurance companies |
Aeglea Bio Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Aeglea Stock often depends not only on the future outlook of the current and potential Aeglea Bio's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Aeglea Bio's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 3.4 M | |
| Cash And Short Term Investments | 55.7 M |
Aeglea Bio Technical Analysis
Aeglea Bio's future price can be derived by breaking down and analyzing its technical indicators over time. Aeglea Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Aeglea Bio Therapeutics. In general, you should focus on analyzing Aeglea Stock price patterns and their correlations with different microeconomic environments and drivers.
Aeglea Bio Predictive Forecast Models
Aeglea Bio's time-series forecasting models is one of many Aeglea Bio's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Aeglea Bio's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Aeglea Bio Therapeutics
Checking the ongoing alerts about Aeglea Bio for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Aeglea Bio Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Aeglea Bio is not yet fully synchronised with the market data | |
| Aeglea Bio has some characteristics of a very speculative penny stock | |
| Aeglea Bio has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 2.33 M. Net Loss for the year was (83.81 M) with loss before overhead, payroll, taxes, and interest of (262 K). | |
| Aeglea Bio Therapeutics currently holds about 73.68 M in cash with (80.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.2, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 98.0% of the company shares are held by institutions such as insurance companies |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Other Consideration for investing in Aeglea Stock
If you are still planning to invest in Aeglea Bio Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aeglea Bio's history and understand the potential risks before investing.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |